NVision team (NVision)
NVision Imaging, an Israeli startup and developer of MRI polarizers and hyperpolarized imaging agents that could help with faster and more accurate cancer diagnosis and treatment, raised $30 million in a Series A round of investment led by Playground Global,, with an additional $19.5M in funding from the German government. The company will use the funds to advance the development and deployment of the NVision Polarizer and “usher in a new era of metabolic MRI capabilities and ultimately, adaptive cancer treatment.”
Israeli high-tech firms and scientists have always been at the forefront of medical research and breakthroughs including cancer. For example, just last week Jewish Business News reported on how Israeli scientists at Tel Aviv University (TAU) and the Sheba Medical Center completed a study that revealed how melanoma cancer cells can form new lymphatic vessels in the dermis, the middle layer of the skin, in order to spread to other parts of the body. The researchers believe that this discovery could lead to new treatments for melanoma, including vaccines.
And, in April, TAU scientists revealed yet another breakthrough in the treatment of cancer. They said they found a way to treat ovarian cancer using RNA-based nanodrugs
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Founded in 2015 by quantum physicists, engineers, and chemists, NVision is a developer of MRI polarizers and hyperpolarized imaging agents. The company’s hyperpolarization technology permits the assessment of human and animal metabolism by standard MRI, enabling advanced preclinical and clinical applications, including novel cancer diagnosis and monitoring of response to therapy. 2023 delivery of first polarizers to users.
Traditional MRIs detect slow-changing effects of a cancer therapy at the tissue level, which can take months to show up from the onset of treatment. Conversely, metabolic MRIs are able to detect early changes of key metabolic pathways at the cellular level, which can show up within days from starting treatment. The challenge is that these metabolic MRIs rely on polarization, which enables the measurement of natural metabolites.
Unlike traditional polarizers that are slow, cumbersome to use, and complicated to operate in the MRI setting, NVision’s Polarizer, baosts the firm, is “fast, robust, and easy-to-use.”
“The impact that this technology will have on medicine is monumental,” said Dr. Sella Brosh, CEO of NVision. “With more accessibility to this kind of technology and giving doctors more time to choose the right therapy for treatment, we can significantly improve a patient’s chance of recovery while not subjecting them to toxic treatments that hurt more than they help. Certainty will become the cornerstone of a new, life-altering era of adaptive cancer treatment that gives patients and their loved ones peace of mind.”
